Abstract
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.
MeSH terms
-
Child
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Drug Design
-
Glatiramer Acetate
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Interferon Type I / adverse effects
-
Interferon Type I / therapeutic use*
-
Multiple Sclerosis / complications
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / pathology
-
Multiple Sclerosis / therapy*
-
Peptides / adverse effects
-
Peptides / therapeutic use*
-
Recombinant Proteins
-
Research Design
-
Treatment Failure
-
Treatment Outcome
Substances
-
Immunosuppressive Agents
-
Interferon Type I
-
Peptides
-
Recombinant Proteins
-
Glatiramer Acetate